Innoviva (NASDAQ:INVA) Reaches New 1-Year High at $19.45

Innoviva, Inc. (NASDAQ:INVA) hit a new 52-week high on Friday . The stock traded as high as $19.45 and last traded at $19.40, with a volume of 197806 shares. The stock had previously closed at $19.10.

Analyst Upgrades and Downgrades

INVA has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Innoviva in a report on Tuesday, July 30th. StockNews.com downgraded Innoviva from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 6th.

Innoviva Price Performance

The firm has a fifty day simple moving average of $17.71 and a 200 day simple moving average of $16.19. The company has a market capitalization of $1.21 billion, a PE ratio of 8.73 and a beta of 0.57. The company has a debt-to-equity ratio of 0.67, a quick ratio of 11.40 and a current ratio of 12.70.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter. Innoviva had a return on equity of 33.26% and a net margin of 44.00%. The business had revenue of $99.90 million for the quarter. Equities analysts anticipate that Innoviva, Inc. will post 0.5 EPS for the current year.

Institutional Trading of Innoviva

Institutional investors have recently made changes to their positions in the business. EdgeRock Capital LLC acquired a new stake in shares of Innoviva in the 2nd quarter worth $31,000. Bessemer Group Inc. boosted its position in shares of Innoviva by 333.5% in the 1st quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 1,701 shares in the last quarter. Innealta Capital LLC acquired a new stake in shares of Innoviva in the 2nd quarter worth $33,000. GAMMA Investing LLC boosted its position in shares of Innoviva by 124.0% in the 1st quarter. GAMMA Investing LLC now owns 2,262 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 1,252 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Innoviva during the 1st quarter worth about $138,000. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.